A Small‐Molecule Inhibitor of Prion Replication and Mutant Prion Protein Toxicity

No abstract is available for this paper.

• Publication year

  2017

• Venue

  ChemMedChem

• Publication date

  2017-08-22

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/cmdc.201700302PMID 28722340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Developing Therapeutics for PrP Prion Diseases.

  2017cited by this paper
• Avoiding Missed Opportunities by Analyzing the Sensitivity of Our Decisions.

  2016cited by this paper
• A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein

  2016cited by this paper
• Common therapeutic strategies for prion and Alzheimer’s diseases

  2016cited by this paper
• Bicyclic octahydrocyclohepta[b]pyrrol-4(1H)one derivatives as novel selective anti-hepatitis C virus agents.

  2016cited by this paper
• Identification of Anti-prion Compounds using a Novel Cellular Assay*

  2016cited by this paper
• Oxidative Dearomatization of 4,5,6,7-Tetrahydro-1H-indoles Obtained by Metal- and Solvent-Free Thermal 5-endo-dig Cyclization: The Route to Erythrina and Lycorine Alkaloids.

  2016cited by this paper
• Decoding the function of the N-terminal tail of the cellular prion protein to inspire novel therapeutic avenues for neurodegenerative diseases.

  2015cited by this paper
• Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy

  2015cited by this paper
• CNS drug design: balancing physicochemical properties for optimal brain exposure.

  2015cited by this paper
• Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold.

  2015cited by this paper
• Prion disease: chemotherapeutic strategies.

  2012cited by this paper
• Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.

  2010cited by this paper
• A Novel, Drug-based, Cellular Assay for the Activity of Neurotoxic Mutants of the Prion Protein*

  2009cited by this paper
• Structure-brain exposure relationships.

  2006cited by this paper
• The public health impact of prion diseases.

  2005cited by this paper
• Transmission dynamics and epidemiology of BSE in British cattle

  1997cited by this paper
• Transmission dynamics and epidemiology of BSE in British cattle

  1996cited by this paper
• Novel proteinaceous infectious particles cause scrapie.

  1982cited by this paper
• 4-amino-4-arylcyclohexanones and their derivatives: a novel class of analgesics. 2. Modification of the carbonyl function.

  1981cited by this paper

• Novel anti-prion compounds screening in prion-infected cell culture model combined with surface plasmon resonance analysis

  2025cites this paper
• Adaptation of the protein misfolding cyclic amplification (PMCA) technique for the screening of anti‐prion compounds

  2024cites this paper
• Are fibrinaloid microclots a cause of autoimmunity in Long Covid and other post-infection diseases?

  2023cites this paper
• Environmental factors modulating protein conformations and their role in protein aggregation diseases.

  2021cites this paper
• Tackling prion diseases: a review of the patent landscape

  2021cites this paper
• Cellular models for discovering prion disease therapeutics: Progress and challenges

  2020cites this paper
• Generation, optimization and characterization of novel anti-prion compounds.

  2020cites this paper